FIELD: medicine.
SUBSTANCE: the present innovation refers to the method for decreasing the rate of cell proliferation of thyroid medullary carcinoma (TMC), the methods of its therapy and visualization which deal with interaction of TMC cells with one or several selective agonists SSTR2 chosen out of the group of compounds consisting of: D-Nal-cyclo[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2; cyclo[Tic-Tyr-D-Trp-Lys-Abu-Phe]; 4-(2-hydroxyethyl)-1-piperazinylacetyl-D-Phe-cyclo(Cys-Tyr-D-Trp-Lys-Abu-Cys)-Thr-NH2 and 4-(2-hydroxyethyl)-1-piperazine-2-ethanesulfonyl-D-Phe-cyclo(Cys-Tyr-D-Trp-Lys-Abu-Cys)-Thr-NH2; or their pharmaceutically acceptable salts. The present innovation enables to decrease the rate of TMC cell proliferation and improve the results of its visualization due to selective agonistic action upon SSTR2 along the absence of undesirable effects upon systemic hemodynamics and the values of body metabolism.
EFFECT: higher efficiency.
10 cl, 8 dwg, 2 tbl
